Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine Prescribed for COVID-19

    June 2020 in “ The Journal of Allergy and Clinical Immunology In Practice ”
    Jérémie Delaleu, Benjamin Deniau, Maxime Battistella, Adèle de Masson, Benoît Bensaïd, M. Jachiet, Ingrid Lazaridou, M. Bagot, Jean‐David Bouaziz, Gordon L. Archer, Anne Bergeron, Anne Bergeron, Louise Bondeelle, Jean‐David Bouaziz, D. Bouda, David Boutboul, Berthon I. Brindel, Emmanuelle Bugnet, S. Caillat Zucman, S. Cassonnet, Karine Celli Lebras, Jacqueline Chabert, Sylvie Chevret, Meredith Edwards, Claire Davoine, Nathalie De Castro, É. de Kerviler, Constance de Margerie‐Mellon, Constance Delaugerre, François Dépret, B. Denis, Lalia Djaghout, Clarisse Dupin, Dominique Farge, Catherine Fauvaux, E. Feredj, Delphine Feyeux, Jean‐Sébastien Fontaine, Véronique Frémeaux‐Bacchi, Lionel Galicier, Stéphanie Harel, Jegu AL, E. Kozakiewicz, Marc Lebel, Ariane Baye, Jennifer Goff, Pierre Le Guen, Nicolas Etienne, Geoffroy Liégeon, Gwenaël Lorillon, I. Madelaine Chambrin, G. Martin de Frémont, Marie Meunier, Jean‐Michel Molina, Florence Morin, Éric Oksenhendler, Régis Peffault de Latour, Olivier Peyrony, Benoît Plaud, Maud Salmona, Julien Saussereau, Juliette Soret
    Studysummary This case study highlights that even short-term use of hydroxychloroquine for COVID-19 can potentially lead to acute generalized exanthematous pustulosis as an adverse effect.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →